Search

Your search keyword '"M. Rendina"' showing total 20 results
Start Over Author "M. Rendina" Journal journal of hepatology
20 results on '"M. Rendina"'

1. Comparison of resistance profiles among DAA-naive and DAA-experienced patients infected with HCV non-1 genotype in Italy

Author

Simona Francioso, A. Ciaccio, Teresa Pollicino, Bianca Bruzzone, G. Fiorentino, V. Boccaccio, Coppola Nicola, M. Puoti, Ivana Maida, Valeria Cento, Lucio Boglione, Francesca Ceccherini Silberstein, Valeria Micheli, Silvia Barbaliscia, Sergio Babudieri, Guido Gubertini, Giustino Parruti, Antonio Craxì, Vincenzo Vullo, Ennio Polilli, M. Andreoni, Filomena Morisco, Vincenzo Sangiovanni, Vincenza Calvaruso, Renato Maserati, Velia Chiara Di Maio, Maurizio Zazzi, Marianna Aragri, A. Ciancio, Barbara Rossetti, Anna Claudia Pellicelli, Elisabetta Teti, C.F. Perno, Caterina Pasquazzi, L. Sarmati, R. D’Ambrosio, Mario Angelico, Fosca Niero, Stefano Bonora, M. Rendina, Gloria Taliani, Luca Foroghi, Laura Ambra Nicolini, Aldo Bertoli, A. Lleo, G. Raimondo, T. Ruggiero, Simona Marenco, Valeria Pace Palitti, G.B. Gaeta, Stefania Paolucci, and Ilaria Lenci

Subjects
Hepatology, Resistance (ecology), business.industry, Genotype, Medicine, business, Virology
Published
2018
Full Text
View/download PDF

2. SVR is the strongest predictor of occurrence and recurrence of hepatocellular carcinoma in HCV cirrhotic patients after treatment with DAAs: a prospective multi-centric Italian study

Author

Vincenza Calvaruso, V. Boccaccio, Pietro Lampertico, Patrick Maisonneuve, Alessio Aghemo, Alessia Giorgini, Giulia Troshina, Elisabetta Degasperi, V. Di Marco, Fabio Conti, Ana Lleo, Maurizia Rossana Brunetto, Massimo Zuin, Simona Bollani, P. Andreone, A. Di Leo, L. Marzi, Barbara Coco, Erica Villa, Marcello Persico, S. Bruno, M. Rendina, Andrea Aglitti, and A. Ciancio

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.disease, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Hepatocellular carcinoma, medicine, 030211 gastroenterology & hepatology, business, After treatment
Published
2018
Full Text
View/download PDF

3. Analysis of Predictive Factors of Non Response to Therapy in Autoimmune Hepatitis-Primary Biliary Cirrhosis Overlap Syndromes a Retrospective Singlecenter Experience

Author

M. Rendina, A. Di Leo, S. Carparelli, Antonio Facciorusso, R. Licinio, and N.M. Castellaneta

Subjects
medicine.medical_specialty, Primary biliary cirrhosis, Hepatology, Response to therapy, business.industry, Internal medicine, medicine, Autoimmune hepatitis, medicine.disease, business, Gastroenterology
Published
2016
Full Text
View/download PDF

5. LP51 : Treatment of severe HCV recurrence after liver transplantation with sofosbuvir based regimen: Results of the aisf-sofolt Italian compassionate use program

Author

Francesco Giuseppe Foschi, Maria Francesca Donato, Raffaella Viganò, P. Burra, Paolo Pianta, Ilaria Lenci, M. Colpani, L. Pasulo, Paola Carrai, Manuela Merli, A. Degli Antoni, Fabio Conti, Pierluigi Toniutto, Federica Malinverno, Antonietta Romano, Francesco Russo, Mariarosa Tamè, Sonia Berardi, Ranka Vukotic, Giuseppe Mazzella, P. Andreone, Laura Loiacono, Stefano Fagiuoli, Rosa Maria Iemmolo, M.C. Morelli, Antonio Picciotto, Luca S. Belli, and M. Rendina

Subjects
Regimen, medicine.medical_specialty, Hepatology, Sofosbuvir, business.industry, medicine.medical_treatment, medicine, Hcv recurrence, Compassionate Use, Liver transplantation, business, medicine.drug, Surgery
Published
2015
Full Text
View/download PDF

6. P0903 : Slow HCV kinetics following sofosbuvir + ribavirin administration in real-life setting of liver transplant recipients with severe recurrent hepatitis C

Author

C. Chialà, R. Canu, Maria Chiara Colombo, Giuseppe Tisone, Francesca Ceccherini-Silberstein, Fausto Zamboni, V.C. Di Maio, Antonio Picciotto, Luciano Milanesi, M. Manuelli, Giorgio Rossi, Ilaria Lenci, A. Di Leo, L. Mameli, M.C. Sorbo, M. Rendina, Daniele Sforza, Roberta Alfieri, Simona Marenco, A. Abedrabbo, Maria Francesca Donato, M.L. Ponti, Martina Milana, R. Ganga, Federica Malinverno, Valeria Cento, C.F. Perno, Marianna Aragri, S. Monico, and Mario Angelico

Subjects
medicine.medical_specialty, Hepatology, Sofosbuvir, business.industry, Ribavirin, Gastroenterology, chemistry.chemical_compound, chemistry, Internal medicine, medicine, In real life, Recurrent hepatitis, business, medicine.drug
Published
2015
Full Text
View/download PDF

7. 523 PROTRACTED ANTIVIRAL TREATMENT BEYOND CONVENTIONAL TIME LIMITS IMPROVES SURVIVAL IN NON-RESPONDERS TO INTERFERON+RIBAVIRIN ADMINISTERED FOR HCV RECURRENCE AFTER LIVER TRANSPLANTATION

Author

Luisa Pasulo, Ezio Fornasiere, P. Burra, L. Miglioresi, Maurizio Pompili, Raffaella Viganò, D. Di Paolo, Valerio Giannelli, Maria Francesca Donato, F.R. Ponziani, M. Rendina, Valentina Rosa Bertuzzo, M. Marino, Matteo Cescon, and Stefano Fagiuoli

Subjects
medicine.medical_specialty, Hepatology, business.industry, Ribavirin, medicine.medical_treatment, Hcv recurrence, Liver transplantation, Gastroenterology, chemistry.chemical_compound, Non responders, chemistry, Interferon, Internal medicine, Medicine, Antiviral treatment, business, medicine.drug
Published
2011
Full Text
View/download PDF

8. P885 RECIPIENT AND DONOR GENDER MATCH PREDICTS THE OUTCOME OF ANTIVIRAL THERAPY FOR RECURRENT HEPATITIS C

Author

Silvia Pecere, F.R. Ponziani, Davide Bitetto, Stefano Fagiuoli, M. Rendina, Francesco Donato, Pierluigi Toniutto, D. Di Paolo, Luisa Pasulo, L. Miglioresi, Manuela Merli, Rosa Maria Iemmolo, Lino Belli, Alessandro Gasbarrini, P. Burra, and M.C. Morelli

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Antiviral therapy, Medicine, Recurrent hepatitis, business, Outcome (game theory)
Published
2014
Full Text
View/download PDF

9. 176 PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDY EVALUATING EFFICACY AND SAFETY OF INTRAVENOUS SILIBININ IN PATIENTS WITH HCV RECURRENCE ON THE GRAFT AFTER LIVER TRANSPLANTATION

Author

Massimo D'Amato, Lucio C. Rovati, S.F. Rizzi, M. Rendina, A. Di Leo, Nadia Brambilla, M. Zappimbulso, R. Bringiotti, Giampaolo Giacovelli, N.M. Castellaneta, and A. Castellaneta

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Hcv recurrence, Silibinin, Liver transplantation, Placebo, Surgery, Double blind, chemistry.chemical_compound, chemistry, Internal medicine, medicine, In patient, business
Published
2013
Full Text
View/download PDF

10. 85 INTERACTION BETWEEN CYCLOSPORINE AND RECIPIENT IL-28B RS12979860 C>T GENETIC POLYMORPHISMS IN THE ACHIEVEMENT OF SUSTAINED VIRAL RESPONSE FOR RECURRENT HEPATITIS C

Author

Stefano Fagiuoli, Edmondo Falleti, Annarosa Cussigh, Ezio Fornasiere, P. Burra, Pierluigi Toniutto, Sara Cmet, Carlo Fabris, Luisa Pasulo, Davide Bitetto, Lino Belli, M. Rendina, T. De Feo, Cristina Rigamonti, F.R. Ponziani, Francesco Donato, Raffaella Viganò, Alessandro Gasbarrini, S. Ginanni-Corradini, and E. De Martin

Subjects
Hepatology, business.industry, Immunology, Sustained viral response, Medicine, Recurrent hepatitis, business
Published
2012
Full Text
View/download PDF

11. 427 TREATMENT OF HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: GENDER ISSUE ON THERAPY OUTCOME

Author

Stefano Fagiuoli, Cristina Lucidi, Raffaella Viganò, D. Di Paolo, M. Rendina, E. De Martin, Pierluigi Toniutto, Michela Giusto, Valerio Giannelli, Francesco Donato, Rosa Maria Iemmolo, M.C. Morelli, L. Miglioresi, Maurizio Pompili, Luisa Pasulo, Manuela Merli, and F.R. Ponziani

Subjects
Therapy Outcome, medicine.medical_specialty, Hepatology, business.industry, General surgery, medicine.medical_treatment, Hepatitis C, Liver transplantation, medicine.disease, University hospital, Gastroenterology, Internal medicine, medicine, business
Abstract

427 TREATMENT OF HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: GENDER ISSUE ON THERAPY OUTCOME V. Giannelli, C. Lucidi, M. Giusto, F.R. Ponziani, M. Pompili, R. Vigano, R.M. Iemmolo, F.M. Donato, M. Rendina, P. Toniutto, L. Pasulo, S. Fagiuoli, M.C. Morelli, E. de Martin, L. Miglioresi, D. di Paolo, M. Merli, RECOLT-C. Sapienza University of Rome, Cattolica Sacro Cuore, Niguarda Ca’Granda Hospital, Rome, Modena University, Modena, Maggiore Hospital, Milan, Bari University, Bari, Udine University, Udine, Bergamo University, Bergamo, Sant’Orsola Malpighi Hospital, Bologna, Padua University Hospital, Padua, San Camillo-Spallanzani Hospital, Tor Vergata University Hospital, Rome, Italy E-mail: mr_valegiann84@hotmail.it

Published
2011
Full Text
View/download PDF

12. 561 BEST MATCHING FOR HCV GENOTYPE 1 LIVER TRANSPLANT RECIPIENTS IS PREDICTED BY HCV1-STAR. A STUDY FROM AISF RECOLT-C DATABASE

Author

F.R. Ponziani, Raffaella Viganò, Valerio Giannelli, A. Milani, Alessandro Gasbarrini, L. Miglioresi, Maurizio Pompili, Rosa Maria Iemmolo, D. Di Paolo, Matteo Cescon, Stefano Fagiuoli, Pierluigi Toniutto, Maria Francesca Donato, M. Rendina, Luisa Pasulo, and E. De Martin

Subjects
Oncology, medicine.medical_specialty, Hepatology, Hcv genotype 1, business.industry, Internal medicine, medicine, Star (graph theory), Best matching, business
Published
2011
Full Text
View/download PDF

13. 551 DONOR-RELATED CHARACTERISTICS AS PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE TO ANTIVIRAL THERAPY IN RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION

Author

G.E. Gerunda, Ezio Fornasiere, M. Marino, Roberto Montalti, Raffaella Viganò, D. Di Paolo, Valerio Giannelli, L. Migliorasi, F.R. Ponziani, Stefano Fagiuoli, Maria Francesca Donato, E. De Martin, M.C. Morelli, Rosa Maria Iemmolo, and M. Rendina

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Virologic response, Internal medicine, medicine, Antiviral therapy, Liver transplantation, Recurrent hepatitis, business, Gastroenterology
Published
2011
Full Text
View/download PDF

14. 532 POOR ADHERENCE TO PEGYLATED-INTERFERON AND RIBAVIRIN IS A MAJOR CONCERN IN THE TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: EVIDENCE FROM THE RECOLT-C GROUP

Author

G. Tisone, Matteo Cescon, Stefano Fagiuoli, L. Miglioresi, M.F. Ponato, D. Di Paolo, M. Rendina, E. De Martin, F.R. Ponziani, Raffaella Viganò, Rosa Maria Iemmolo, Mario Angelico, Pierluigi Toniutto, and Manuela Merli

Subjects
medicine.medical_specialty, Hepatology, business.industry, Ribavirin, medicine.medical_treatment, Liver transplantation, Gastroenterology, Virology, Poor adherence, chemistry.chemical_compound, chemistry, Pegylated interferon, Internal medicine, Medicine, Recurrent hepatitis, business, medicine.drug
Published
2011
Full Text
View/download PDF

15. 578 IS THE PRIMARY IMMUNOSUPPRESSIVE DRUG (CYCLOSPORIN A OR TACROLIMUS) PLAYING A ROLE ON THE RESPONSE TO ANTIVIRAL TREATMENT FOR POST-TRANSPLANT HCV RECURRENCE?

Author

D. Di Paolo, F.R. Ponziani, Pierluigi Toniutto, Raffaella Viganò, Valerio Giannelli, L. Miglioresi, Stefano Fagiuoli, Matteo Cescon, Maria Francesca Donato, M. Marino, M. Rendina, V. Vero, E. De Martin, Marco Senzolo, and Luisa Pasulo

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Hcv recurrence, Post transplant, Tacrolimus, Immunosuppressive drug, Cyclosporin a, Internal medicine, Medicine, Antiviral treatment, business
Published
2011
Full Text
View/download PDF

16. 563 ACUTE AND CHRONIC REJECTION DURING INTERFERON THERAPY IN HCV RECURRENT TRANSPLANT PATIENTS: RESULTS FORM THE AISF-RECOLT-C GROUP

Author

Valerio Giannelli, D. Di Paolo, Maria Francesca Donato, M. Rendina, F.R. Ponziani, P. Burra, Raffaella Viganò, Pierluigi Toniutto, L. Miglioresi, Rosa Maria Iemmolo, Stefano Fagiuoli, Luisa Pasulo, M.C. Morelli, A. Di Leo, and N.M. Castellaneta

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Interferon therapy, Medicine, Transplant patient, business, Gastroenterology
Published
2011
Full Text
View/download PDF

17. 464 TREATMENT OF THE 'UNCOMMON' HCV GENOTYPE 4 INFECTION RECURRENCE AFTER LIVER TRANSPLANTATION. AN ITALIAN MULTICENTRIC EXPERIENCE

Author

Maurizio Pompili, F.R. Ponziani, Valerio Giannelli, E. De Martin, A. Milani, M.C. Morelli, Maria Francesca Donato, Pierluigi Toniutto, Luisa Pasulo, M. Marino, Raffaella Viganò, Alessandro Gasbarrini, Stefano Fagiuoli, D. Di Paolo, L. Miglioresi, and M. Rendina

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Internal medicine, Genotype, medicine, Liver transplantation, business, Gastroenterology
Published
2011
Full Text
View/download PDF

18. 579 THE PRESENCE OF DIABETES REDUCES SVR AFTER ANTIVIRAL THERAPY FOR POST-TRANSPLANT HCV RECURRENCE

Author

Pierluigi Toniutto, V. Vero, E. De Martin, M. Rendina, L. Miglioresi, Raffaella Viganò, D. Di Paolo, F.R. Ponziani, Valerio Giannelli, Stefano Fagiuoli, Maria Francesca Donato, M. Marino, Matteo Cescon, Marco Senzolo, and Luisa Pasulo

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Diabetes mellitus, Internal medicine, Antiviral therapy, Medicine, Hcv recurrence, business, medicine.disease, Post transplant
Published
2011
Full Text
View/download PDF

19. Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis.

Author

Di Cola S, D'Amico G, Caraceni P, Schepis F, Loredana S, Lampertico P, Toniutto P, Martini S, Maimone S, Colecchia A, Svegliati Barone G, Alessandria C, Aghemo A, Crocè SL, Adinolfi LE, Rendina M, Lapenna L, Pompili E, Zaccherini G, Saltini D, Iavarone M, Tosetti G, Martelletti C, Nassisi V, Ferrarese A, Giovo I, Masetti C, Pugliese N, Campigotto M, Nevola R, and Merli M

Subjects
Humans, Male, Female, Middle Aged, Prospective Studies, Prognosis, Aged, Tomography, X-Ray Computed methods, Hospitalization statistics & numerical data, Incidence, Prevalence, Sarcopenia epidemiology, Sarcopenia diagnosis, Sarcopenia etiology, Sarcopenia complications, Liver Cirrhosis complications
Abstract

Background & Aims: Sarcopenia and myosteatosis are common in patients with cirrhosis. This study aimed to determine the prevalence of these muscle changes, their interrelations and their prognostic impact over a 12-month period., Methods: We conducted a prospective multicentre study involving 433 patients. Sarcopenia and myosteatosis were evaluated using computed tomography scans. The 1-year cumulative incidence of relevant events was assessed by competing risk analysis. We used a Fine-Gray model adjusted for known prognostic factors to evaluate the impact of sarcopenia and myosteatosis on mortality, hospitalization, and liver decompensation., Results: At enrolment, 166 patients presented with isolated myosteatosis, 36 with isolated sarcopenia, 135 with combined sarcopenia and myosteatosis and 96 patients showed no muscle changes. The 1-year cumulative incidence of death in patients with either sarcopenia and myosteatosis (13.8%) or isolated myosteatosis (13.4%) was over twice that of patients without muscle changes (5.2%) or with isolated sarcopenia (5.6%). The adjusted sub-hazard ratio for death in patients with muscle changes was 1.36 (95% CI 0.99-1.86, p = 0.058). The cumulative incidence of hospitalization was significantly higher in patients with combined sarcopenia and myosteatosis than in patients without muscle changes (adjusted sub-hazard ratio 1.18, 95% CI 1.04-1.35). The cumulative incidence of liver decompensation was greater in patients with combined sarcopenia and myosteatosis (p = 0.018) and those with isolated sarcopenia (p = 0.046) than in patients without muscle changes. Lastly, we found a strong correlation of function tests and frailty scores with the presence of muscle changes., Conclusions: Myosteatosis, whether alone or combined with sarcopenia, is highly prevalent in patients with cirrhosis and is associated with significantly worse outcomes. The prognostic role of sarcopenia should always be evaluated in relation to the presence of myosteatosis., Impact and Implications: This study investigates the prognostic role of muscle changes in patients with cirrhosis. The novelty of this study is its multicentre, prospective nature and the fact that it distinguishes between the impact of individual muscle changes and their combination on prognosis in cirrhosis. This study highlights the prognostic role of myosteatosis, especially when combined with sarcopenia. On the other hand, the relevance of sarcopenia could be mitigated when considered together with myosteatosis. The implication from these findings is that sarcopenia should never be evaluated individually and that myosteatosis may play a dominant role in the prognosis of patients with cirrhosis., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)

Published
2024
Full Text
View/download PDF

20. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant.

Author

Rendina M, Schena A, Castellaneta NM, Losito F, Amoruso AC, Stallone G, Schena FP, Di Leo A, and Francavilla A

Subjects
Adult, Drug Therapy, Combination, Female, Follow-Up Studies, Hepacivirus drug effects, Hepacivirus metabolism, Hepatitis C, Chronic complications, Hepatitis C, Chronic virology, Humans, Injections, Subcutaneous, Interferon alpha-2, Kidney Failure, Chronic etiology, Kidney Failure, Chronic therapy, Kidney Transplantation, Male, Middle Aged, Pilot Projects, Preoperative Care, RNA, Viral blood, Recombinant Proteins, Treatment Outcome, Antiviral Agents administration & dosage, Hepatitis C, Chronic drug therapy, Interferon-alpha administration & dosage, Polyethylene Glycols administration & dosage, Renal Dialysis, Ribavirin administration & dosage
Abstract

Background/aims: We undertook a pilot study to investigate the efficacy and safety of peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed chronic HCV patients awaiting renal transplant., Methods: Patients received peginterferon alfa-2a 135 microg/week plus ribavirin 200 mg/day for 24 or 48 weeks (genotype non-1 and 1, respectively). The dose of ribavirin was tailored according to plasma concentrations and to haemoglobin levels. Outcomes in treated patients were compared with those of a matched untreated control group., Results: Thirty-five patients received treatment, while 35 served as untreated controls. Thirty patients completed treatment; patients were withdrawn due to transplantation (n=2), severe anaemia (n=1), dermatitis (n=1) and non-response (n=1) resulting in a drop-out rate of 14%. Overall, 34/35 treated patients were HCV RNA negative at week 4 and had undetectable RNA at the end of treatment, compared with none of the untreated controls (ETR 97% vs 0%; p<0.001). Moreover, all achieved sustained virological response after 24 weeks of treatment-free follow-up versus no control patients (SVR 97% vs 0 %; p<0.001)., Conclusions: In this study, we have shown for the first time in a large cohort of patients that HCV-patients on haemodialysis can be treated successfully with peginterferon alfa-2a (40 kDa) plus ribavirin.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results